Delcath Systems Inc.
Clinical trials sponsored by Delcath Systems Inc., explained in plain language.
Medical device company developing liver-directed cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New combo targets liver tumors in hard-to-treat colorectal cancer Results expected Dec 2026 (estimated)
-
New trial aims High-Dose chemo directly at liver tumors in breast cancer patients
Disease control Recruiting nowThis phase 2 trial tests whether delivering high-dose chemotherapy directly to the liver (using a special system) followed by standard cancer drugs works better than standard drugs alone for people with breast cancer that has spread mainly to the liver. About 90 participants will…
Phase 2 • Sponsor: Delcath Systems Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New combo targets liver tumors in hard-to-treat colorectal cancer
Disease control Recruiting nowThis study tests whether giving a strong chemotherapy directly to the liver, followed by standard cancer pills and an injection, works better than the standard treatment alone. It is for people whose colorectal cancer has spread mostly to the liver and is no longer responding to …
Phase 2 • Sponsor: Delcath Systems Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC